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Abstract
The increasing commercial demand for L-carnitine has led to a multiplication of efforts to improve
its production with bacteria. The use of different cell environments, such as growing, resting,
permeabilized, dried, osmotically stressed, freely suspended and immobilized cells, to maintain
enzymes sufficiently active for L-carnitine production is discussed in the text. The different cell
states of enterobacteria, such as Escherichia coli and Proteus sp., which can be used to produce L-
carnitine from crotonobetaine or D-carnitine as substrate, are analyzed. Moreover, the combined
application of both bioprocess and metabolic engineering has allowed a deeper understanding of
the main factors controlling the production process, such as energy depletion and the alteration of
the acetyl-CoA/CoA ratio which are coupled to the end of the biotransformation. Furthermore,
the profiles of key central metabolic activities such as the TCA cycle, the glyoxylate shunt and the
acetate metabolism are seen to be closely interrelated and affect the biotransformation efficiency.
Although genetically modified strains have been obtained, new strain improvement strategies are
still needed, especially in Escherichia coli as a model organism for molecular biology studies. This
review aims to summarize and update the state of the art in L-carnitine production using E. coli and
Proteus sp, emphasizing the importance of proper reactor design and operation strategies, together
with metabolic engineering aspects and the need for feed-back between wet and in silico work to
optimize this biotransformation.
Introduction
In general, in a biotransformation involving whole cells
(either using growing, resting or even permeabilized
cells), proper process operation and optimum production
depends on the optimization of different variables.
Among these, we may include (i) the physicochemical
conditions of operation for maximum active enzyme con-
centration per unit of cell (protein synthesis, activity and/
or stability), such as pH, temperature, osmolarity and the
presence of activators/inhibitors, (ii) the concentration of
both the catalyst and the substrate being used, (iii) the
biocatalytic environment (i.e. reactor type), (iv) the opti-
mization scheme, which, in turn, depends on the bioproc-
ess studied, and (v) strain improvement strategies. Last
but not least, enzymes involved in the bioprocess can be
either constitutive or induced in certain conditions of cell
growth. Optimization must look at both bioreactor and
strain optimization and, in both fields, the development
of suitable models would enable the correct decisions to
be undertaken. In either case, process optimization
requires a step by step scheme of variable optimization, as
will be presented below.
L-carnitine (R(-)-3-hydroxy-4-trimethylaminobutyrate) is
an ubiquitous compound, found in animal and vegetal
tissues, as well as in microorganisms. The best character-
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ized role of L-carnitine is the transport of long-chain fatty
acids through the inner mitochondrial membrane: its
involvement in the metabolism of heart, liver, muscle,
brain and adipose tissues, as well as a certain role in sperm
maturation, the immune system and connecting tissue
have been well established [1]. Moreover, several clinical
applications have been identified for this compound,
which has led to increased demand worldwide and to the
development of new production methods [1-3].
In the last 30 years, the feasibility of producing L-carnitine
from waste products of the chemical industry, such as cro-
tonobetaine or D-carnitine, by whole cell catalyzed
biotransformations using E. coli and Proteus sp strains has
focused the interest of both industry and applied science.
The production of L-carnitine by biotransformation with
E. coli and Proteus sp. strains is a good case-study to illus-
trate the feed-back between fundamental and applied
research. The main aim of this review is to update the
knowledge on bacterial carnitine metabolism (fundamen-
tal research) and the potential industrial application of its
production methods (applied research), focusing on both
bioprocess development and strain optimisation strate-
gies.
1. Bacterial metabolism of L-carnitine
1.1. Assimilation and/or biotransformation of L-carnitine by 
microorganisms
Although the role of L-carnitine is well established in
eukaryotes, it is not so clear in bacteria [4]. The existence
of uptake systems with different degrees of specificity in
both gram positive and negative bacteria has been related
with its protective properties. The ProP and ProU systems
of E. coli, and the OpuC of B. subtillis have been shown to
be involved in carnitine uptake under osmotic stress con-
ditions [4-7]. Moreover, in some species, such as Listeria
monocitogenes, the existence of betaine uptake systems has
been related to protection against other stress conditions
such as low temperatures [8] and to its ability to grow and
survive in foods and to provoke infections in vivo [9].
In addition to the protective roles exhibited after accumu-
lating betaines, some bacterial species are also able to
metabolize these trimethylammonium compounds under
different conditions [4]. Depending on the species and
the cultivation conditions (carbon and nitrogen sources,
aerobic or anaerobic conditions), different pathways are
involved in L-carnitine catabolism. The initial enzymes of
the various catabolic pathways are induced by L-carnitine,
but also partly by other trimethylammonium com-
pounds. Different genera are able to degrade L-carnitine
under aerobic conditions, assimilating both carbon and
nitrogen in the molecule backbone. Some Pseudomonas
species (like Pseudomonas aeruginosa A7244 and Pseu-
domonas sp. AK1) are able to grow aerobically on L-carni-
tine as the sole source of carbon and nitrogen (Fig. 1A). In
these species, L-carnitine degradation starts by oxidation
of the hydroxyl group with the concomitant formation of
3-dehydrocarnitine by an L-carnitine dehydrogenase (EC
1.1.1.108) [10]. Pseudomonas sp. AK1 is also able to grow
on γ-butyrobetaine, which is an intermediate in the degra-
dation pathway [11]. This pathway has similarities with
the biosynthetic pathway of L-carnitine in eukaryotes (Fig.
1A).
Furthermore, some species like Acinetobacter calcoaceticus
69/V are not able to assimilate nitrogen from the L-carni-
tine skeleton and degradation occurs with the stoichio-
metrical formation of trimethylamine [12] (Fig. 1A). This
bacteria is able to metabolize L-carnitine, L-O-acylcarni-
tines and γ-butyrobetaine as sole carbon source. D-carni-
tine can also be metabolized but only in the presence of L-
carnitine to act as an inducer [12]. The stereoselectivity
L-carnitine metabolism in bacteria Figure 1
L-carnitine metabolism in bacteria. A) Schematic representa-
tion of the main pathways for L(-)-carnitine metabolization in 
bacteria. Shaded and striped reactions correspond to the 
pathways observed in Enterobacteria and Acinetobacter 
strains, respectively. Reactions in the dashed box correspond 
to Pseudomonas strains. Enzymes or "systems" involved: 1, γ-
butyrobetaine hydroxylase; 2, L-carnitine dehydrogenase; 3, 
L-carnitine dehydratase; 3a, "carnitinyl-CoA hydrolase"; 4, 
crotonobetaine reductase; 4a, "γ-butyrobetaine dehydroge-
nase"; 5, monooxygenase; 6, "carnitine racemase"; 7, D-carni-
tine dehydrogenase. Adapted from [4]. B) Complete 
anaerobic biotransformation pathway for trimethylammo-
nium compounds in E. coli. Adapted from [30]. Abbreviations: 
Crot, crotonobetaine; γ-BB, γ-butyrobetaine, L-Car, L-carni-
tine; D-Car, D-carnitine; Gly, glycine; 3-dehydro-Car, 3-
dehydrocarnitine; Me3N, trimethylamine; Mal, malate; Suc, 
succinate; CaiT, L-carnitine/γ-butyrobetaine/crotonobetaine 
protein transporter; CaiA, CaiB, crotonobetaine reduction 
reaction; CaiB, CoA transferase; CaiC, L-carnitine/γ-buty-
robetaine/crotonobetaine CoA ligase; CaiD, enoyl-CoA 
hydratase or carnitine racemase activity.Microbial Cell Factories 2007, 6:31 http://www.microbialcellfactories.com/content/6/1/31
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observed in the metabolism of this strain could be a result
of the existence of two separate transport systems for D-
and L-isomers, since the wild-type strain A. calcoaceticus
ATCC 39647 exhibits enantiomer discrimination due to
the differential cell membrane permeability [13].
Finally, Enterobacteriaceae, such as E. coli, Salmonella typh-
imurium,  Proteus vulgaris and  Proteus mirabilis, do not
assimilate the carbon and nitrogen skeleton of trimethyl-
ammonium compounds, but are able to metabolize carni-
tine,  via  crotonobetaine, to γ-butyrobetaine [4]. The
presence of adequate carbon and nitrogen sources during
anaerobic (and in some cases also aerobic) growth is nec-
essary for proper expression of the genes for components
of the biotransformation machinery. Further, the
biotransformation can also occur in the absence of nutri-
ents, as has been shown in studies with resting cells [14].
Although the D-enantiomer does not exist in nature,
interestingly, various bacteria are able to further cat-
abolize or biotransform it [4,14].
1.2. L-carnitine pathway in Enterobacteria: E. coli and Proteus sp
Initially, a two-step pathway was proposed for L-carnitine
metabolization in E. coli and Proteus sp. strains, including
two enzyme activities: L-carnitine dehydratase (CDH, EC
4.2.1.89) and crotonobetaine reductase (CR, EC 1.3.99)
[15,16] (Fig 1A). Subsequently, carnitine racemase activ-
ity (CRac), interconverting the D- and L-isomers, was also
described [17]. The cloning of the cai operon in E. coli [18]
and Proteus sp. [19] showed a higher degree of complexity,
and also pointed to similar organization and high degree
of homology between both strains. Six ORFs were found
and functions were first assigned on the basis of sequence
homology, and later experimentally demonstrated (Table
1). Recent studies have deciphered the roles of almost all
cai operon gene products (Fig 1B). Thus, CaiT is a highly
specific transporter working as antiporter, allowing sub-
strate and product exchange [20,21]. The biotransforma-
tion occurs at the level of CoA derivatives [22,23], while
the initially described CDH and CR activities were shown
to depend on two proteins (enoyl-CoA hydratase, CaiD,
EC 4.2.1.89, and crotonobetainyl-CoA reductase, CaiA,
EC 1.3.99, respectively) both needing the joint action of a
transferase (crotonobetainyl-CoA:carnitine CoA trans-
ferase, CaiB, EC 2.8.3) to allow the CoA-cycling between
products and substrates of the biotransformation [24,25].
CaiC (betainyl-CoA ligase, EC 6.2.1) has been shown to
catalyze the synthesis of the CoA-derivatives of trimethyl-
ammonium compounds, which are the substrates of both
CaiD and CaiA activities [26]. The only function which
remains unconfirmed is that of CaiE, although early over-
production experiments pointed to an activation of the
CaiD/CaiB function (CDH activity, Fig. 1A), suggesting a
possible role as a cofactor of these enzymes [18].
A seventh ORF, the caiF  gene, which is located down-
stream of the cai operon and is transcribed in the opposite
direction to this, has been cloned [19,27] (Table 1). The
product is a transcriptional factor which, in E. coli, is syn-
thesized when cells are grown under anaerobiosis and in
the absence of glucose as carbon source. In the presence of
L-carnitine, CaiF becomes active, and is able to induce the
expression of cai  genes [28]. High regulation of this
metabolism has been demonstrated in E. coli and Proteus
sp. strains. Transcription of the cai operon is induced dur-
ing anaerobic growth in the presence of L-carnitine and
occurs as a polycistronic mRNA. The expression of caiF-
lacZ and caiT-lacZ fusions is enhanced 20- and 200-fold,
respectively, when cells are grown under anaerobic condi-
tions [27,29]. In terms of enzyme activities, when cells are
grown under aerobiosis, carnitine dehydratase (CDH) has
been reported to be 3-fold higher, while no crotono-
betaine reductase (CR) can be detected [30]. As regards
the expression mechanism, the activator of carbon cata-
bolic operons, CRP, is required for induction. In addition,
the histone-like H-NS protein and the σS factor (RpoS),
which is involved in gene regulation in stationary-phase,
exert a repressive effect on carnitine metabolism [18,29].
The mechanism of repression remains unknown,
although there is evidence that it probably operates at the
level of caiF expression [27].
Table 1: Comparison of cai operon codified proteins in E. coli and Proteus sp. strains [4,15,19]
Gene Protein length (aa) Function of gene product Homology (%) Reference
E. coli Proteus sp.
caiT 504 504 Transport protein* 88 [20,21]
caiA 380 380 Crotonobetainyl-CoA reductase 93 [16,65]
caiB 405 406 Betainyl-CoA transferase 86 [22,24,25]
caiC 524 518 Betainyl-CoA ligase* 69 [26]
caiD 297 261 Crotonobetainyl-CoA hydratase 82 [24,25,60]
caiE 203 197 Unknown 76 [15,19]
caiF 131 130 Transcriptional regulator* 51 [19,27]
(*) In Proteus sp. strain, function postulated on the basis of sequence similarities [19].Microbial Cell Factories 2007, 6:31 http://www.microbialcellfactories.com/content/6/1/31
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It should be mentioned the fact that caiF is the gene hav-
ing the lowest homology between both species (Table 1)
and that alterations in its promoter region have been pro-
posed as being responsible for the very different regula-
tion of this pathway in Proteus sp. [19].
Another operon composed of four ORFs was found in E.
coli at the 5' end of the cai locus in E. coli. It was shown to
be co-transcribed from the same promoter/operator
region [31] and the corresponding proteins displayed sig-
nificant sequence homology with polypeptides encoded
by the fixABCX operon from Azorhizobium caulinodans and
Rhizobium meliloti, and were therefore named fix. This
operon has been confirmed as being involved in electron
transfer to crotonobetaine [32]. Deletion studies have also
shown that part of the fix sequence is necessary for the
proper expression of cai operon [29].
Despite all this accumulated knowledge, the precise func-
tion of this reaction sequence in Enterobacteria remains
unknown. Seim et al., postulated that crotonobetaine
serves as an external electron acceptor of anaerobic respi-
ration similar to nitrate, fumarate and trimethylamine-N-
oxide [33,34]. The stimulation of anaerobic growth in
Enterobacteria by crotonobetaine and the suppression of
this reaction by nitrate or glucose certainly support this
hypothesis. The functional characterization of the CaiT
transport system as an antiporter for L-carnitine and γ-
butyrobetaine [20] is also in accordance with this idea and
would explain why this kind of transporter cannot be
involved in osmoprotection [6,35]. However, the induc-
tion under aerobic conditions of carnitine metabolism in
several Enterobacteriaceae [23,36], including Proteus
strains, suggests a possible loss of function due to muta-
tions affecting the regulation of this pathway. In addition
to these functions, some results show that microorgan-
isms of the gastrointestinal tract may play a role in lower-
ing the concentration of dietary L-carnitine [4,33].
2. Overview of current methods for L-carnitine production
2.1. Chemical methods for L-carnitine production
Much research effort has focused on the development of
methods for the industrial scale production of L-carnitine.
Numerous chemical procedures can be found in the liter-
ature involving asymmetric synthesis [37-39]; chemical
multistep racemization [40]; resolution through diasteroi-
someric derivatives [41-43]; microbiological or enzymatic
techniques [44-47] and the use of chiral starting materials
[48-50]. For instance, the method developed by Bellamy
et al. [49], consisted of six steps which, using as starting
material (R)- and (S)-malic acid, respectively, specifically
obtaining both enantiomers. More recently, Marzi et al.
[51] described an enantioselective synthesis using achiral
glycerol as starting material and a chiral auxiliary. How-
ever, few of these chemical procedures are of practical use
on an industrial scale because of the number of steps, and
the need to use of chiral starting materials or chiral auxil-
iaries. The classical industrial method for the synthesis of
carnitine generates a racemic mixture, with D-carnitine as
waste product [41].
2.2. Biotechnological methods for L-carnitine production
The potential advantages of biotechnological methods
employing both enzymes and microorganisms have
encouraged extensive research into the microbial metabo-
lism of L-carnitine and its derivatives [2,4,46,47,52].
These methods mostly aim at using industrial waste prod-
ucts (such as D-carnitine, crotonobetaine or γ-buty-
robetaine) as substrates. In addition, biotechnological
procedures have other advantages over chemical proc-
esses. Compared with the classical chemical method of
racemate synthesis involving resolution of the enantiom-
ers, the enantioselective production of racemate by fed-
batch cultivation of a Rhizobium-like strain, involves 50%
less total organic waste, 25% less waste water and 90%
less waste for incineration [2,53].
The most commonly used starting materials for the pro-
duction of L-carnitine are achiral precursors (mostly crot-
onobetaine, γ-butyrobetaine and 3-dehydrocarnitine) or
racemic mixtures (such as D, L-acyl-carnitine, D, L-carniti-
namide and D, L-carnitine) [2,4,41,46,52]. A great variety
of microorganisms can be used for these biotransforma-
tions (Table 2). Since the early 1980s, many companies
worldwide have patented bioprocesses for L-carnitine pro-
duction (Seitetsu, Kyowa Hakko, Chou Kaseihih, Toyo
Jozo, Ajinomoto, Sigma Tau, Lonza, Nippon Pet Food,
Yakult Honsha, Elf Aquitaine, Sanofi) [2]. As an example,
while bioprocesses developed for commercial production
of L-carnitine by Sigma Tau (Italy) are based on the
biotransformation of crotonobetaine by E. coli and Proteus
mirabilis strains, Lonza (Switzerland) uses γ-butyrobetaine
as starting material and a derivative of the HK4 strain. This
latter strain was isolated from a soil sample and its path-
way from γ-butyrobetaine to L-carnitine is analogous but
not identical to fatty acid degradation. Taxonomically,
this bacteria would be between Agrobacterium and Rhizo-
bium, close to Rhizobium meliloti [52]. This strain was able
to grow on L-carnitine as the sole source of carbon and
nitrogen under aerobic conditions, while the degradation
of L-carnitine was blocked by frameshift mutagenesis, giv-
ing rise to a derivative strain, HK13, lacking L-carnitine
dehydrogenase [53]. Similarly, several Cai proteins of E.
coli  show a high degree of homology with enzymes
involved in fatty acid degradation, such as acyl-CoA dehy-
drogenase and CaiA, acetate-CoA ligase and CaiC, and
enoyl-CoA hydratase and CaiD [18].
Although the productivities reported for E. coli strains are
not the highest found in the literature, the genomic andMicrobial Cell Factories 2007, 6:31 http://www.microbialcellfactories.com/content/6/1/31
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metabolic constraints controlling L-carnitine metabolism
are well-characterized. In addition, L-carnitine production
using this microorganism has the main advantage of its
well demonstrated capacity for high density cultivation
[54,55], its resistance to immobilization [56,57] and to
environmental stresses during bioprocesses [30,35] and
the availability of well established molecular biology
techniques, allowing the application of top-down strate-
gies for bioprocess optimization. Consequently, the main
factors affecting the production of L-carnitine with both
wild type and genetically engineered E. coli strains will be
reviewed. In addition, comparisons will also be made
with Proteus sp. which possesses a very similar carnitine
metabolism [19,23], somewhat better bioprocess per-
formance [58,59], and promises very interesting improve-
ments.
L-carnitine production with E. coli and Proteus sp. 
strains: bioprocess optimization
1. Effect of inducers and oxygen on metabolizing activities
The capacity of E. coli and Proteus sp. cells to produce L-car-
nitine by biotransformation of either crotonobetaine or
D-carnitine has been shown to be inducible. The proper
biotransformation capacity is only induced in the pres-
ence of compounds such as crotonobetaine, D-carnitine
or even L-carnitine in the growth medium [17]. Maximal
biotransformation capacity (determined as specific L-car-
nitine dehydratase activity, CDH) is induced in the pres-
ence of 5 mM crotonobetaine in anaerobiosis. In
addition, under production conditions, CDH activity
remains high since both the substrate and the product of
the bioprocess are inducers. Both Proteus and E. coli are
able to synthesize the above mentioned L-carnitine
metabolism-dependent enzymes: carnitine dehydratase
and crotonobetaine reductase [16,25,60]. L-carnitine pro-
duction can reach 50–65% (molar yield), depending on
the strain, cells and substrate concentration and the run-
ning conditions. In addition, variable amounts of the side
product  γ-butyrobetaine can be detected (Fig. 1)
[14,25,61,62]. In fact, γ-butyrobetaine is always pro-
duced, especially during the growth phase, but also, at a
lower rate during the resting cell production process.
The effect of aerobic/anaerobic conditions on the induc-
tion of L-carnitine metabolism and on the biotransforma-
tion performance was also explored. For this, cells were
induced in aerobic and anaerobic conditions and both
cell cultures were used for biotransformation in resting.
The biotransformation using resting cells was also per-
formed under both aerobic and anaerobic conditions
(100 mM crotonobetaine, 4 g l-1 biomass, pH 7.5 and
37°C). When non genetically engineered E. coli strains
were grown aerobically, no L(-)-carnitine production was
observed. In the case of E. coli K38 pT7-5KE32 strain,
which overexpresses both CaiF and CaiD proteins, when
growth and induction were performed aerobically, up to
1.5 g L-1 h-1 L-carnitine (yield: 38.2%) were produced, in
contrast to the 11.3 g L-1 h-1 (yield, 70.1%) produced in
anaerobic conditions [61]. Moreover, the best results were
obtained using anaerobiosis for the carnitine metabolism
induction phase and aerobiosis for the biotransformation
of crotonobetaine into L-carnitine [14]. In the case of the
non-transformed E. coli O44K74 strain, when comparing
anaerobic and aerobic conditions for the biotransforma-
tion using cells grown under anaerobic conditions, pro-
ductivities of 0.18 g L-1 h-1, and 0.21 g L-1 h-1 (34 and 39%
molar yield) respectively, were obtained [14]. Up to a
53.2% L-carnitine yield was obtained with E. coli pT7-
5KE32 after 2 h incubation in anaerobic conditions,
which meant a productivity of 10.3 g L-1 h-1, whereas aer-
obic biotransformation provided 70.1% product yield in
1 h, the productivity being 11.3 g L-1 h-1 [61]. Thus, both
yield and productivity were higher when the cells were
induced during anaerobic growth, meaning that anaerobi-
Table 2: Microorganisms used for L-carnitine production from chiral and achiral substrates and the enzyme activities involved. 
Adapted from [2].
Substrates Activities involved Microorganism
Achiral 
precursors
Crotonobetaine L-carnitine dehydratase E. coli, Proteus mirabilis, Acinetobacter lwoffi, Achromobacter 
xylosoxydans
γ-butyrobetaine γ-butyrobetaine hydroxylase HK4, HK13, HK1349 (taxonomically between Rhizobium and 
Agrobacterium), Saccharomyces cerevisiae, Penicillium, Rhizopus, 
Mucor, Actinomucor, Neurospora, Aspergillus, Achromobacter, 
Pseudomonas, Nocardia crassa
3-dehydrocarnitine L-carnitine dehydrogenase (NADH dependent) Agrobacterium, Pseudomonas
Racemic 
mixtures
D, L-carnitinenitrile Nitrilase Corynebacterium sp.
D, L-acyl-carnitine Acyl-L-carnitine esterases Fusarium oxysporum sp. lini, Corynebacterium, Bacillus, Pseudomonas
D, L-carnitineamide Carnitine amidase Pseudomonas sp., DSM 6320 (Agrobacterium or Sphingomonas sp.)
D, L-carnitine Carnitine racemase Pseudomonas sp., E. coli
D(+)-carnitine assimilation Acinetobacter calcoaceticus Acinetobacter lwoffiMicrobial Cell Factories 2007, 6:31 http://www.microbialcellfactories.com/content/6/1/31
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osis was the preferred condition for carnitine metabolism
induction, while aerobic conditions yield increased
biotransformation performance.
A more in-depth analysis of the effect of oxygen levels per-
mitted conditions to be optimized [63,64] and showed
that  γ-butyrobetaine production was dramatically
decreased when the biotransformation was performed
under aerobic conditions as a consequence of the inhibi-
tion of crotonobetaine reductase by oxygen
[14,16,63,65]. Other compounds known to be electron
acceptors for E. coli were checked for their ability to inhibit
γ-butyrobetaine production and enhance L-carnitine yield
under anaerobic conditions, but worthwhile results were
only obtained with fumarate [14].
In the case of the Proteus sp. strain, γ-butyrobetaine pro-
duction has been shown to be much lower both with
growing and resting cells, although has been observed in
high cell density reactors, in which oxygen limitations can
occur [58]. Crotonobetaine reductase activity has been
detected in cell free extracts, meaning that impaired expor-
tation of γ-butyrobetaine might occur [19,23].
2. Biotransformation with D-carnitine or crotonobetaine as 
substrates
As already mentioned, both D-carnitine and crotono-
betaine can be used as biotransformation substrates. Nev-
ertheless, the different levels of carnitine dehydratase and
carnitine racemase activities explain why the highest pro-
ductivities are achieved with crotonobetaine [63]. In addi-
tion, the production of L-carnitine from D-carnitine is
only possible if production experiments are performed
under fully or partially aerobic conditions with both
growing and resting cells [14,63]. Increased productivity
was obtained using a genetically modified strain overpro-
ducing the multifunctional protein CaiD, which is part of
both carnitine dehydratase (CDH) and carnitine racemase
(CRac) activities [61]. In this overproducing strain, E. coli
K38 pT7-5KE32, the level of the respective enzyme activi-
ties responsible for the biotransformation correlated well
with the productivity obtained using each substrate, since
carnitine dehydratase activity approximately doubled the
level of carnitine racemase.
3. The implications of transport phenomena for bioprocess 
optimization: three different strategies
Many works have underlined the importance of the kinet-
ics of substrate uptake and product efflux for the develop-
ment of bioprocesses using whole cells [66]. The
engineering of transport phenomena allows for the
improvement of bioprocesses through various strategies.
Although membrane integrity is necessary for maintain-
ing the chemical independence of the cell from the extra-
cellular medium, and is essential for cell survival, many
so-called cell permeabilization methods have been devel-
oped to improve the biotransformation process [67,68].
These methods can greatly affect membrane structure and
low (or even high) molecular weight compounds may
leak out of the cell (e.g. cofactors), not only compromis-
ing cell viability, but also bioprocess performance. How-
ever, in bioprocesses in which growth and
biotransformation are uncoupled, cell proliferation is not
necessary to maintain productivity.
Besides, the molecular composition of bacterial mem-
brane can be engineered in order to increase the occur-
rence of membrane transporters. L-carnitine, as well as
other betaines, are osmoprotectants, which means that
bacteria can accumulate them intracellularly in order to
allow them to cope with high extracellular amounts of
osmotically active compounds [6,35,69,70]. Thus, cells
were subjected to salt stress conditions in order to induce
the expression of the betaine transporters involved in
osmoprotection, with the aim of tuning up cellular L-car-
nitine uptake rates [6,71] (Fig. 2A). Finally, the applica-
L-carnitine transport systems in E. coli strains Figure 2
L-carnitine transport systems in E. coli strains. A) Main char-
acteristics of L-carnitine transporters: CaiT: carnitine/crot-
onobetaine/γ-butyrobetaine antiporter [20]; ProU and ProP, 
osmotic stress related transporters [6,69]. B) Effect of per-
meabilizers on cell envelope and outer membrane Adapted 
from [76].Microbial Cell Factories 2007, 6:31 http://www.microbialcellfactories.com/content/6/1/31
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tion of molecular biology techniques allows specific
targeting of the overexpression of selected genes, such as
that of the antiporter CaiT [72].
3.1. Permeabilization of E. coli and Proteus sp. cells
Gram-negative bacteria like E. coli possess a mechanically
strong cell envelope made up largely of peptidoglycan,
which gives the cells shape and protects them from
osmotic lysis (Fig 2B). Outside this layer, there is an addi-
tional outer membrane (OM), whose role is mainly pro-
tective and which is less selective and more permeable
than the cytoplasmic membrane. The OM functions as an
efficient barrier against hydrophilic macromolecules and
hydrophobic substances due to a specific lipopolysaccha-
ride layer on the membrane surface. The integrity of the
cell envelop (in general) and even of the OM (gram-nega-
tive bacteria) can be disturbed by permeabilizers, such as
detergents (Triton X-100 and Tween), EDTA, organic sol-
vents (toluene, lactic acid and alcohols) and certain poly-
cationic substances (such as polyethylenimine,
polymyxin and its derivatives, polylysines and protamine)
[73-76].
As previously seen in many other biotechnologically rele-
vant systems, the substrate (crotonobetaine) uptake and
product (L-carnitine) efflux are controlled by diffusion
through both the outer membrane (OM) and cell enve-
lope, together with the membrane transport system itself
(CaiT) (Fig 2B) [77]. Cell damage and integrity during
permeabilization has been assessed by fluorescent probe
uptake assays (such as 1-phenylnaphthylamine or NPN)
[78], protein cell leakage, transmission electron micros-
copy (cell structural alterations) and transport assays with
L [N-methyl14C]carnitine (specific carrier transport stud-
ies) [76]. Both E. coli and Proteus sp. cells were treated for
different times and at different permeabilizer concentra-
tions, during batch cell growth. After permeabilization
treatment, the culture broth was centrifuged and cells
were resuspended in the biotransformation medium (cro-
tonobetaine in phosphate buffer) for 48 h. For Proteus sp.,
Triton X-100 resulted in higher conversion and productiv-
ity values than those of the control (Fig. 3A). An increase
in L-carnitine molar yield of more than 50% was achieved
in both growing and resting biotransformation media
[79]. For E. coli O44K74, an almost 100% increase in yield
was observed (Fig. 3B) [76], with polyethylenimine (PEI)
being the best permeabilizer. Transmission electron
microscopy of Proteus sp. and E. coli cells after permeabili-
zation demonstrated that the cell wall was affected while
the membrane remained intact, meaning that crotono-
betaine/L-carnitine transporter could work faster and far
more efficiently (Fig. 2B).
More recently, a new method for the permeabilization of
E. coli has been developed. The mutation of lpp, which
encodes Braun's lipoprotein, a major component of the
outer membrane, does not affect cell growth and metabo-
lism and increases the rate of whole cell-catalyzed reac-
tions in which substrate diffusion is known to be a
controlling factor. The authors reported a 30% increase in
the molar yield of L-carnitine production (up to 56%)
when using resting cells carrying this mutation [77].
It should be remarked that by permeabilizing the cell, a
biotransformation unit containing a cofactor-regenerat-
ing system (CaiC and CaiB enzymes, Fig. 1B) would be
deviced, the efficiency of the biocatalytic process being
increased. Thus permeabilized cells offer an interesting
alternative to the often-addressed problem of coenzyme
regeneration.
3.2. Overproduction of CaiT
In the case of trimethylammonium compounds metabo-
lism, the expression of cai operon leads to the presence in
the membrane of the specific antiporter CaiT. In E. coli,
CaiT protein has been stated to be highly specific and able
to work independently of cellular energy [20]. However,
the cell state may affect the degree of multimerization of
the transporter, which has been proposed as being
involved in its activity [21]. The CaiT protein of Proteus sp.
is unable to excrete γ-butyrobetaine, thus explaining why
this compound is not detected extracellularly in this pro-
duction strain (Bernal et al., unpublished results). The
Effect of different transport engineering strategies on L-carni- tine production Figure 3
Effect of different transport engineering strategies on L-carni-
tine production. Permeabilization of Proteus sp. (A) and E. coli 
O44K74 (B) cells using detergents and organics. L-carnitine 
production by E. coli O44K74 under salt stress conditions 
(C). Bar represents productivity and lines the yield. PEI 
stands for polyethylenimine. Adapted from [76,79].Microbial Cell Factories 2007, 6:31 http://www.microbialcellfactories.com/content/6/1/31
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increase in carnitine production by permeabilized cells
[76,77,79] or after salt treatment [71], underlines the con-
trol that transport exerts on this biotechnological process.
When  caiT  was cloned and overexpressed in E. coli
LMG194 (a standard laboratory strain), an almost 3-fold
increase in L-carnitine molar yield was obtained with both
growing and resting cells [72]. However, the level of pro-
duction of L-carnitine, in the engineered strain was still far
from that of the E. coli O44K74 strain (6.9 vs 37.5
mmol·gDCW
-1). Thus, although transport limits L-carni-
tine production, it is not the main factor controlling the
biotransformation in laboratory strains [26]. However,
further work is necessary to determine the effect of the
overexpression of other transporters on L-carnitine pro-
duction. Furthermore, the occurrence of metabolite trans-
porters in bacterial genomes has to be considered in the
possible light of a physiological role. In the case of amino
acid production strains, uptake may be physiologically
significant, while the interest of excretion is less obvious,
only being explained in certain cases by overflow metab-
olism, limited catabolism and deregulated anabolism, a
fact that has been considered in strain development stud-
ies [66]. In this case, CaiT is the only transporter involved
in L-carnitine uptake under standard salt concentrations
(unpublished data), while it has already been demon-
strated not to be involved in osmoprotection [6], which is
a consequence of the antiport mechanism of transport
[20].
3.3. Effect of salt stress on the biotransformation
Despite the importance of osmotic stress phenomena in
the determination of cell survival and growth in impor-
tant systems of study such as food, water and bioproc-
esses, there is little information available on their effect on
cell metabolism [80]. Betaine uptake systems have been
described in E. coli, which are involved in osmoprotec-
tion. In fact, the intracellular accumulation of osmotically
active compounds (compatible solutes) allows the cell to
cope with several stress conditions [7]. In E. coli, the ProU
and ProP (Fig. 2A) systems have been described as being
regulated to deal with these stress conditions, both being
energy-consuming [7,69,70]. Despite this, CaiT is not
involved in stress adaptation [6] and in stress situations
carnitine metabolization is inhibited in growing cells
[4,71]. However, metabolism alterations that follow
osmotic stress adaptation improve L-carnitine production
in resting cells, and perturbation studies revealed a regula-
tion in the main pathways involved in ATP production
and in the balancing of anabolism and catabolism [35].
Furthermore, the effect of salt stress on biotransforma-
tions should be considered, since both substrates and
products are osmoprotectants. Therefore, the biotransfor-
mation of D-carnitine or crotonobetaine into L-carnitine
by resting cells of E. coli strains under different salt stress
conditions was studied.
Cells were grown and the biotransformation assays car-
ried out with resting cells in aerobiosis in the presence of
different NaCl concentrations. The maximum L-carnitine
yield obtained for control resting cells was 40–45%,
depending on the substrate and its concentration [71]. L-
carnitine production from crotonobetaine was enhanced
when the NaCl concentration was increased to 0.5 M,
reaching 85–90% yield for E. coli pT7-5KE32 (Fig. 3C); no
improvement was obtained at higher NaCl concentra-
tions. On the contrary, the effect of salt stress on the
biotransformation of D-carnitine in L-carnitine was dele-
terious (yield control values were 20–22% for both
strains), since the carnitine racemase activity is negatively
affected by high ionic strength when assayed in cell-free
extracts [4].
4. Biocatalyst optimization: reuse and reactivation of freely 
suspended and immobilized cells
When using non-growing bacterial cells as biocatalyst, the
biomass growth phase is usually more time consuming
than the biotransformation phase. The possibility of reus-
ing cells allows to greatly increase bioprocess productivity,
while diminishing the amount of growth medium needed
for catalyst production. In addition, in the successive
cycles of operation, the biotransformation capacity of
cells may be lost, as seen with Agrobacterium sp., Proteus sp.
and E. coli cells [59,62,81], which suggests cofactor leak or
degeneration or even a decrease in the cell enzyme level.
Thus biocatalyst regeneration should be regarded as
essential.
In the case of E. coli cells, since the biotransformation
occurred in a short period of time (1–10 h, depending on
cell strains), while the growth phase was slow (15 h), the
possibility of reusing the resting cells was checked. With
the more slowly biotransforming strains (non trans-
formed E. coli O44K74, for instance) a decrease in L-carni-
tine productivity during successive cycles of
biotransformation has been observed. However, the
biotransformation capacity could be recovered if after
each biotransformation cycle (16 h) a regeneration cycle
was followed (8 h incubation in fresh growth medium)
[62]. The analysis of resting cells state by means of flow
cytometry revealed a decrease in cell viability during the
first 15–24 h, coinciding with the end of the biotransfor-
mation [82]. Thus, de-energization of resting cells and,
probably, also cofactor leak or degradation, are a major
drawback for continuous use in biotransformation.
A different scenario was found in the case of the geneti-
cally engineered strain E. coli pT7-5KE32. This engineered
strain overproduce the L-carnitine dehydratase activityMicrobial Cell Factories 2007, 6:31 http://www.microbialcellfactories.com/content/6/1/31
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[61], thus allowing for a very short run time (1 h). During
successive cycles of biotransformation, product yield was
maintained over 50% for eight reuse steps, only decreas-
ing 16% during this time [79]. This reuse of biomass per-
mitted about an 8-fold increase in the amount of L-
carnitine produced per gram of cells. Thus, the short run
time also allowed the reuse of cells, since cell viability was
not affected, and the productivity remained well above
50% after eight reuse cycles. A single biotransformation
process took 16 h, (14 h for cell growth and 2 h for both
cell harvesting and the biotransformation process), to
produce 2.7 g L-carnitine per gram of biomass. After eight
reuse cycles, 20 g L-carnitine g-1 cells were produced in 30
h; this means that seven growth phases were avoided, total
process time being reduced from 128 to 30 h. The amount
of L-carnitine produced per gram of cells was increased 8-
fold, consequently improving overall efficiency of the bio-
process [79].
Moreover, with Proteus mirabilis a decrease in productivity
was also observed during successive cycles, although this
has been demonstrated to be partially attenuated when
cells are immobilized, meaning that mechanical stress
might also be involved [59]. In addition, cell immobiliza-
tion is an advantage for cell reuse [56,59].
Therefore, the use of recombinant microorganisms
together with the reuse of the biocatalyst (immobilized or
not) always leads to increased efficiency of these produc-
tion systems.
5. Biotransformation using growing and resting cycles in immobilized 
cell reactors for cell activation
In order to increase the productivity of the biotransforma-
tion, immobilization methods can be applied. The ade-
quate selection of solid support material is necessary to
attain high productivities. When using packed bed reac-
tors with solid supports, such as polyurethane foam and
glass beads, higher L-carnitine productivities have been
reported (1.8 g·l-1·h-1, 26% yield) [56] than when using
polyacrylamide (0.3 g·l-1·h-1) [83]. In the case of Proteus
mirabilis in poly (vinyl alcohol) cryogels, yields of over
40% and a productivity of 0.72 g L-1 g-1
biomass h-1 have been
reported (Table 3) [59]. Moreover, these processes were
run by alternating growing and resting cycles so that cell
activation would allow continuous production processes
(see previous section).
In order to optimise the continuous production of L-car-
nitine, the suitability of using a cross-flow filtration mod-
ule (with flat-sheets) and hollow-fiber devices for the
retention of cells within the system has also been checked.
To attain high productivities by means of high cell density
continuous cultivation, microfiltration reactors seem to
be suitable since the accumulation of toxic by-products is
avoided [54,55]. Further, membrane reactors can also be
used with alternating growing and resting cells cycles so
that a cheaper process might result [55,58,63].
Thus, systems equipped with three different membrane
types were studied: cellulose membranes of 300 kDa
nominal cut-off, polysulphonated polysulphone mem-
branes of 0.2 µm nominal cut-off and ceramic mem-
branes of 0.1 µm nominal cut-off. The continuous reactor
system was a CSTR plugged into the membrane system, in
this way in situ separating cells and the product. Operation
was performed at a 1.5–1.8 h-1 dilution rate, using the E.
coli O44K74 strain (Table 3). No important differences
were observed and it was concluded that membrane com-
position had little influence on reactor performance as
similar productivities were obtained.
In order to compare operational stability for different
membrane configurations, a new reactor set-up based on
a hollow-fiber cartridge module with fibers made of
polysulphone, with a total surface available of 0.03 m2,
was used. Throughout the set of experiments, high-cell
density membrane reactors were run at different dilution
rates and growing and resting periods were alternated. In
this way, the continuous production of L-carnitine was as
high as 12 g·L-1·h-1 and the operation remained stable for
long periods of time [63].
Moreover, these membrane reactors have also been
shown to be useful for high cell density cultivation of Pro-
teus sp., reaching up to 35–45 g·L-1 dry biomass retained,
similar to values reported for other microorganisms
[54,58]. In addition, the suitability of this bioreaction sys-
tem for biotransformation was demonstrated by reaching
35–50% yield of conversion and productivities as high as
40.5 g·L-1·h-1 [58]. However, the susceptibility of Proteus
sp. to this bioprocess scheme was shown to be high, as
observed by the high biomass decay during resting cycles,
similar to what has been reported in batch systems [59]
and, thus, optimization work should be performed in
order to stabilize cells.
With both microorganisms, performance was much better
in terms of both biomass and process stability when hol-
low fiber rather than flat sheet membranes were used, the
former permitting long-term cultivation experiments. Fur-
thermore, the degree of adherence of the cake layers to the
membranes was lower in the hollow fiber system. These
features led to increased productivity with Proteus sp.,
while with E. coli lower productivities were attained,
despite the higher biomass levels, due to a lower degree of
induction of the biotransformation pathway [63]. Thus,
the influence of membrane composition should be
checked in each particular case, since interspecies varia-
tions might occur.Microbial Cell Factories 2007, 6:31 http://www.microbialcellfactories.com/content/6/1/31
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Finally, it should be mentioned that, in terms of conver-
sion, the best results so far obtained are those reported
using the Rhizobium-like, HK1349 strain and γ-buty-
robetaine as substrate. In fact, conversion in the range of
90–95% and productivities of up to 5.4 g·L-1·h-1 have
been reported in cell recycle reactors. Moreover, the proc-
ess was scalable to up to 2500 L, but the production costs
were high compared with the fed-batch operated process,
despite the lower productivity attained (about 75% lower,
99% conversion) [84].
6. Analysis of cell state in bioreactors: cellular metabolism and 
physiology
The conditions of bioreactor operation have a profound
impact on cell physiology. For biotechnological applica-
tions, high cell densities are desirable, but metabolic lim-
itations are more likely to arise under these conditions,
even in continuously fed systems (fed-batch, semi-contin-
uous and continuous reactors), putting cell viability at
risk. Under these conditions, cells can enter doubtfully
viable, non-dividing states [85] which, nevertheless, can
be metabolically active [57]. The application of flow
cytometry allows the cell physiological state (as deter-
mined by differential uptake of fluorescent probes by
cells) to be related with bioreactor performance, thus link-
ing the micro- and macro-scale levels of the biotransfor-
mation.
Given the importance of the cell state in the determina-
tion of final bioprocess yield, cells have been classified
into viable intact, viable but non-culturable and dead cells
[86]. Thus, for optimization purposes, research on the
ideal cell state for a given biotransformation needs to be
carried out. Double fluorescent staining of cells with pro-
Table 3: L-carnitine productivities reported in the literature for different batch and continuous systems with growing and resting cells. 
See text for further details.
Batch Growing Cells
Strain Productivity Molar yield (%) Comment Ref.
E. coli O44K74 0.34 g·L-1·h-1 32 Anaerobic 56
Proteus mirabilis 0.72 g L-1 g-1 40 poly(vinyl alcohol) cryogels 59
E. coli LMG194 pBADcaiC 1,7 g h-1 g-1 42 Overexpression of CaiC 26
E. coli BW25113 ∆aceA 2.88 g h-1 g-1 24 Suppression of glyoxylate shunt 26
E. coli BW25113 ∆aceK 3.17 g h-1 g-1 22 Suppression of glyoxylate shunt 26
Resting Cells
Strain Productivity Molar yield (%) Comment Ref.
E. coli pT7-5KE32 4.3 g·L-1·h-1 53.2 Anaerobiosis 61
E. coli pT7-5KE32 11.3 g·L-1·h-1 70.1 Aerobiosis 61
Proteus sp. 6.1 g·L-1·h- 50 Aerobiosis 79
Agrobacterium sp. 525a 1,2 g·L-1·h-1 38 D-Carnitine 781
E. coli O44K74 0.55 g·L-1·h-1 44 D-carnitine 14
E. coli pT7-5KE32 0.90 g·L-1·h-1 40 D-carnitine 62
E. coli O44K74 2.6 g·L-1·h-1 65 Salt Stress 71
E. coli pT7-5KE32 3.2 g·L-1·h-1 80 Salt Stress 71
E. coli O44K74 3.6 g·L-1·h-1 89 Polyethylenimine Permeabilized Cells 76
E. coli pT7-5KE32 3.8 g·L-1·h-1 94 Polyethylenimine Permeabilized Cells 76
Proteus sp. 1.6 g·L-1·g-1·h-1 68 Triton X-100 Permeabilized Cells 79
Continuous Processes
Strain Productivity Molar yield (%) Comment Ref.
Escherichia coli O44K74 0.3 g·L-1·h-1 --- Immobilized in polyacrylamide 83
Escherichia coli O44K74 1.8 g·L-1·h-1 26 Immobilized in glass beads or polyurethane foam 56
E. coli O44K74 6.2–12 g·L-1·h-1 40 Cell recycle 55,63
E. coli pT7-5KE32 1.2 g·L-1·h-1 24 Cell recycle (plasmid loss after 4–6 days) 63
E. coli pT7-5KE32 0.71 g·L-1·h-1 10 Immobilized in kappa-carrageenan 63
Proteus sp. 40.5 g·L-1·h-1 35–50% Cell-recycle 58
Proteobacteria 5.4 g·L-1·h-1 90–95 Cell-recycle 84Microbial Cell Factories 2007, 6:31 http://www.microbialcellfactories.com/content/6/1/31
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pidium iodide and bis-oxonol [86] allows us to determine
population kinetics in bioreactors. In resting cell systems,
cell physiology decays rapidly as a result of the lack of cul-
ture medium [82]. In addition, trimethylammonium
compounds, which are osmoprotectant [70], have a pro-
tecting effect on cells during the biotransformation. Sur-
prisingly, cell state upon high cell density cultivation in
cell recycle reactors was characterized by high levels of via-
bility (Fig. 4A, less than 15% of depolarized cells in the
steady state) [82]. When cells were immobilized in κ-car-
rageenan gel beads, a high accumulation of damaged cells
was observed (less than 10–15% of cells retaining mem-
brane polarity in the steady state) (Fig. 4B) [57]. This
result is of great importance, since it underlines the fact
that cells with somewhat uncertain viability can also be
active producers as a result of maintaining the carnitine
metabolism still active.
Bioprocess and metabolic modelling for L-carnitine 
production with E. coli strains
Modelling is the most rational way of optimizing bioproc-
esses, since it not only allows for a more accurate descrip-
tion of production kinetics, but also for the application of
optimization approaches [87] and the design of a strain
improvement program [88,89]. Quantification of growth
and product formation kinetics, as well as the assessment
of metabolic fluxes, are a requirement for a detailed
knowledge of cellular metabolism. In addition, changes
in the ratios of induction of the main metabolic pathways
under different reactor configurations or growth condi-
tions should be measured both at enzyme/protein and
transcript levels [30,90,91]. Taken together, these studies
would enable the determination of feasible optimisation
targets and might also allow the application of genetic
engineering techniques [92]. Molecular biology tech-
niques are now available for tailor-made strain develop-
ment, especially in the case of certain bacteria (such as E.
coli, B. subtillis, L. lactis) and yeasts (S. cerevisiae, P. pas-
toris). Moreover, of note is the effect of single-gene knock-
out mutants on microbial physiology [93,94]. Below, the
work carried out on metabolic and bioprocess modelling
to further our knowledge of the L-carnitine metabolism is
summarized.
1. Link between central and secondary metabolism during 
biotransformation
Metabolic engineering has been defined as the purposeful
modification of intermediary metabolism using recom-
binant DNA technology [88,89]. The term metabolic engi-
neering was first defined by Bailey [92], who underlined
the central role of Molecular Biology as a tool in Meta-
bolic Engineering. Nevertheless, a proper cellular meta-
bolic state can also be chosen by confining the cell in a
well defined physiological state through a purposeful
design of cultivation techniques [95].
Although this field deals with the redirection of metabolic
fluxes for complete pathways rather than for the improve-
ment of biotransformations performed by a single or a
few enzymatic steps, the application of its concepts is of
great interest as regards the turnover of energy, ATP, and
the regeneration of the cofactors which are required in
biotransformations [96,97]. Thus, in bioprocesses such as
the transformation of trimethylammonium compounds,
in which substrate and product transport and activation
are associated to energy and the performance of the bio-
process involves the mobilization of cellular cofactors,
strain improvement by metabolic engineering is also a
strategy of prime importance, since new cell catalysts can
be purposely devised [26,72]. In fact, when optimizing
bioprocesses that depend on bacterial secondary metabo-
lism, most efforts have been addressed to the increase in
expression level or amplification of gene dosage in sec-
ondary pathways. However, for high cluster copy or high
levels of expression, there seem to be limitations some-
where else in the metabolism, which cause a shift to a
more complex regulation, as exemplified in the metabolic
engineering optimization of β-lactam production [98,99].
In this case, the insufficient supply of precursors from the
primary metabolism, or the accumulation [26] or insuffi-
cient production [99] and even depletion [100] of certain
cellular cofactors can be pointed to as feasible control fac-
tors. Moreover, the applicability of cofactor engineering in
bioprocesses in which the unbalanced regeneration of
Physiological state of E. coli strains during continuous L-carni- tine production: A) High density cell-recycle reactor using E.  coli O44K74; B) Continuous stirred tank reactor with κ-car- rageenan gel immobilized E. coli K38 pT7-5KE32 cells Figure 4
Physiological state of E. coli strains during continuous L-carni-
tine production: A) High density cell-recycle reactor using E. 
coli O44K74; B) Continuous stirred tank reactor with κ-car-
rageenan gel immobilized E. coli K38 pT7-5KE32 cells. Bars 
represent the amount of viable (low bar), depolarized (mid-
dle bar) and dead cells (top bar) [57,82] whereas lines repre-
sent dry cell weight.Microbial Cell Factories 2007, 6:31 http://www.microbialcellfactories.com/content/6/1/31
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cofactors occurs has been demonstrated, both for the
alteration of the cellular redox state [96,101,102] and the
acetyl-CoA/CoA ratio [96,103]. Since cell physiology
must not be compromised under the production condi-
tions, metabolic alterations should be controlled in order
to enable a proper functioning of the metabolic networks
involved.
In the case of carnitine production, the link or connection
between central and secondary metabolisms was seen to
rely on the level of cofactors [22,30]. In fact, energy deple-
tion and an altered acetyl-CoA/CoA ratio were coupled to
the end of the biotransformation. Moreover, the regula-
tory profiles of key central metabolic activities involved in
the regulation of the acetyl-CoA/CoA ratio, such as the
TCA cycle, the glyoxylate shunt and the acetate metabo-
lism were closely interrelated and exercised a control on
the biotransformation efficiency [26,30,104] (Fig. 5).
Moreover, to determine control points in the metabolism
of production strains, we analysed the dynamic evolution
of the central metabolism after perturbations affecting the
level of carbon sources, biotransformation substrate or
electron acceptors. The results underlined the fact that
both ATP levels and the availability of free CoA depended
on cellular metabolism under production conditions
[100]. Furthermore, suboptimal energetic state of E. coli
upon high cell density cultivation conditions limited
maximum productivity because of the low level of betaine
activation. In addition, changes in gene expression, as
reflected by altered levels of enzyme activity and external
metabolite fluxes, were a result of the rapid modification
of metabolite pools after pulses, revealing the ability of
bacterial metabolism to redirect fluxes in order to restore
the steady state conditions.
Metabolic Flux Analysis further substantiated the impor-
tance of the cellular energetic state for the biotransforma-
tion [105]. The results demonstrated a need for a high
amount of ATP to be devoted to the biotransformation
process. This is not only because it is consumed for the
transport and activation of trimethylammonium com-
pounds, but also because of a feasible futile cycle, which
could be detected by the analysis of the network's topol-
ogy. This is a consequence of the simultaneous operation
of the two trimethylammonium compound carriers, CaiT
and ProU [6,69] (Fig. 2A) which leads to energy dissipa-
tion. Moreover, novel strategies for the improvement of
the bioprocess using functional knock-out mutants can be
predicted. This is also an illustration of the fact that, in
addition to the occurrence of merely metabolic control
factors, such as the lack of adequate levels of cofactors or
precursors for biosynthesis, transport limitations can
occur during biotransformations (see previous section).
Finally, a novel application of the modelling of intracellu-
lar processes is the inclusion of signalling networks in
models [106], which opens up new ways for bioprocess
optimization and control strategies, widening monitoring
possibilities.
2. Modelling L-carnitine production: unstructured and structured 
reactor models
Unstructured models use simple equations with few vari-
ables, each contributing a physical meaning, while struc-
tured models use a wide number of variables which take
into account that a cell is composed of many components
each reacting with the others. In general, unstructured
models are based on Monod's rate equations, where
growth depends on biomass concentration as well as on a
sole limiting substrate. Although this means a huge sim-
plification of microbial behaviour, the ability to describe
system kinetics has been widely demonstrated. An
unstructured model of L-carnitine production with E. coli
Simplified model for the interaction of L-carnitine production  pathway with central metabolism of E. coli strains Figure 5
Simplified model for the interaction of L-carnitine production 
pathway with central metabolism of E. coli strains. The main 
pathways involved (and their codifying genes) are shown. 
Central metabolism: AceK (aceK), isocitrate dehydrogenase 
phosphatase/kinase; ACK (ackA), acetate kinase; ACS (acs), 
acetyl-CoA synthetase; ICDH (icd), isocitrate dehydrogenase; 
ICL (aceA), isocitrate lyase; ICLR (iclR), repressor of the gly-
oxylate shunt; MDH (maeB), malate dehydrogenase; ME 
(sfcA), malic enzyme; PEPCK (pckA), phosphoenolpyruvate 
carboxykinase; PFL (pflB), pyruvate:formate lyase; PTA (pta), 
phosphotransacetylase; FumR (frdABCD), fumarate reductase. 
L(-)-carnitine pathway: CaiB: carnitine:CoA transferase; 
CaiC: betaine:CoA ligase; CaiD, enoyl-CoA hydratase; CaiT, 
carnitine/crotonobetaine/γ-butyrobetaine transporter. Path-
way regulators are shown in red. Steps which are not func-
tional under anaerobiosis are shown with grey arrows. 
Adapted from [30].Microbial Cell Factories 2007, 6:31 http://www.microbialcellfactories.com/content/6/1/31
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strains has been developed. In addition, the inclusion of
inhibition/activation functions to describe the oxygen-
dependence on substrate consumption and on the induc-
tion of L-carnitine metabolism allowed modelling of the
effect of this variable on the bioprocess [64]. The model
was applicable to continuous and batch bioprocesses,
both with growing and resting cells, representing the link
between cellular metabolic productivity and the macroki-
netics of the material mass balance for the reactor. In a sec-
ond step, this simple model allowed the establishment of
an S-system description of the cell-bioreactor combined
system, which could, in turn, be used to optimize the bio-
technological setup [107]. The Indirect Optimization
Method [87] was also applied, determining that the dilu-
tion rate, the initial crotonobetaine concentration, and
the carnitine dehydratase activity were of critical impor-
tance for maximizing L-carnitine production. In fact, a
74% increase in the L-carnitine production rate was exper-
imentally assessed, performance which was in close agree-
ment with the predictions of the model. In accordance
with the optimized solution, a further improvement (90%
increase in the L-carnitine production rate) could be
attained by increasing up to 5 times the carnitine dehy-
dratase basal activity.
3. Metabolic engineering for cell improvement: feed-back between 
modelling and experimental analysis of cell metabolism
Although the work described represented the first two
steps in the modelling of the biotransformation process, a
connection with the central and secondary metabolism
was still needed to fully describe the activity of the strain.
In fact, the application of optimization strategies to such
unstructured models can only predict improvement strat-
egies regarding the cultivation method. Therefore, a com-
bined model of reactor and metabolism, linking the
macrokinetics of the reactor with the cellular microkinet-
ics, was developed, and was demonstrated to be useful for
the establishment of genetic engineering strategies [108].
The model showed control points at macroscopic (reactor
operation) and microscopic (molecular) levels where con-
version and productivity could be increased. The opti-
mized solution suggested to increase the levels of the CoA
transferase activity, CaiB, and the protein carrier, CaiT as
the main targets to improve the L-(-)-carnitine production
rate, predicting an enhancement of up to three times the
initial productivity [108].
These results have been experimentally validated, since by
increasing the levels of CaiB and CaiT proteins in the low-
producing E. coli LMG194 laboratory strain, L-carnitine
production could be increased 3–4-fold (Fig 6) [72]. Nev-
ertheless, the effect of CaiC overproduction, enhancing L-
carnitine yield 50-fold in E. coli LMG194 (a 2–3-fold
increase compared with the overproducing E. coli O44K74
strain), was not predicted by this model [26]. The main
reason was that at the time that the model was built, the
kinetic characteristics of this protein were not known [18].
This fact underlines an important concern: the construc-
tion of meaningful models strongly depends on the com-
pleteness and goodness of the data available. Moreover, a
continuous feed-back between in silico and in vivo experi-
mentation is necessary for the application of Metabolic
Engineering and Systems Biology approaches to living sys-
tems [72]. In this context, L-carnitine production with
genetically engineered E. coli cells with certain central
metabolism encoding enzymes deleted, such as pta (phos-
photransferase), acs (acetylCoA synthetase), aceA (isoci-
trate lyase), aceK  (isocitrate dehydrogenase) and iclR
(aceA inhibition), has been determined (Fig. 7). The
results have important implications for the model built to
represent this biotransformation, underlining that proper
expression of the central metabolism, affecting balanced
cofactor levels (acetyl-CoA/CoA in this case), influences
secondary metabolism pathways [26].
Future perspectives
The main limitation of using E. coli for this biotransforma-
tion process is the fact that the carnitine metabolism is
induced under anaerobic conditions, since the expression
of caiF is prevented in the presence of oxygen (Fig. 1)
L-carnitine production with genetically engineered E. coli  cells: effect of gene overexpression on the production of L- carnitine in E. coli Figure 6
L-carnitine production with genetically engineered E. coli 
cells: effect of gene overexpression on the production of L-
carnitine in E. coli. Experiments were performed in batch 
anaerobic systems in L-Broth (black bars) and L-Broth sup-
plemented with 2 g·L-1 fumarate (grey bars). Overproduction 
of CaiT, CaiB and CaiC was performed using pBAD24 as 
expression vector and E. coli LMG194 [F- ∆lacX74 galE galK 
thi rpsL ∆phoA (PvuII) ∆ara714 leu::Tn10] as expression host. 
Control experiments with the non genetically engineered 
overexpressing E. coli O44K74 strain are shown for compari-
son. Adapted from [26,72].Microbial Cell Factories 2007, 6:31 http://www.microbialcellfactories.com/content/6/1/31
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[4,29], and glycerol has to be used as the main carbon
source, since PTS sugars inhibit its expression. In the case
of Proteus sp., PTS sugars also inhibit the carnitine metab-
olism expression, but the biotransformation occurs read-
ily under aerobic conditions [23]. Previous work has
shown that the inhibition of carnitine metabolism by oxy-
gen can be avoided by engineering caiF  expression
[29,63,64]. Furthermore, on-going work focuses on the
development of biochemical systems to avoid PTS sugars
inhibition [106], carrying out the biotransformation
under energetically more favourable conditions. Also, het-
erogenic C-sources, which are cheaper for industrial pur-
poses, could be used, since these would not pose any
diauxie problem either. This is presently under study by
our group.
Conclusion
The present knowledge on bacterial carnitine metabolism
and the potential industrial application of its production
methods focuses on both bioprocess development and
strain optimization. This article has presented an overview
on how genetically engineered and wild-type cells in their
growing, resting and permeabilized states can be used for
the development of biotechnological processes such as
the production of L-carnitine. More importantly, the tri-
methylammonium compounds metabolism of E. coli and
Proteus sp. was found to exercise an important degree of
control on the process, which enabled the application of
metabolic engineering approaches. The need for a bal-
anced connection between the primary and secondary
metabolisms, the transport of the biotransformation sub-
strate/product and the activation of the carnitine interme-
diaries involved in bioprocess has been underlined.
Besides this, E. coli's physiology in production conditions,
is now better understood and different reactor configura-
tions for process optimization are also possible. Further-
more, the design of unstructured and structured models of
the bioprocess has allowed development of novel optimi-
zation strategies, closing the iteration-cycle between the in
silico and in vivo approaches of analysis of this biotransfor-
mation process.
A combination of strategies should lead to the optimized
performance of the biotransformation. The choice of
batch or continuous systems mainly depends on the diffi-
culties involved in the scaling-up processes. In general,
batch systems are preferred in industry, while the perme-
abilization, immobilization or reutilization of cells would
improve bioprocess costs. The most promising guidelines
for strain development would include the overproduction
of the carnitine activation enzymes (CaiB and CaiC),
together with the trimethylammonium compounds trans-
porter (CaiT) and the down-regulation of the expression
of the glyoxylate shunt. Furthermore, the use of chromo-
somal insertion technologies would ensure strain stability
during the bioprocess.
Although biotransformation processes are designed on a
case-by-case basis, the experimental and theoretical meth-
odologies of Bioprocess and Metabolic Engineering are
applicable to the development of any bioprocess involv-
ing whole cells. To further understanding of the function-
ing of any biotransformation process, state-of-the-art
modelling and optimization techniques, in combination
with a study of the genome, transcriptome and proteome,
as well as of the regulome, will lead to new approaches to
understand these bioprocesses. These approaches are cur-
rently being applied in our laboratory for the improve-
ment of bioprocesses carried out by E. coli strains.
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